

**eTable 1.** List of SARS-CoV-2 RT-PCR testing criteria over the study period.

**eTable 2.** List of COVID-19 cohort wards. Inpatients were admitted to these COVID-19 cohort wards during the study period. Both laboratory confirmed and suspected COVID-19 patients were admitted to the cohort wards, except for two wards (COV\_KNKINF and COV\_KITEHO) to which only laboratory confirmed cases were admitted.

**eTable 3.** Estimated SARS-CoV-2 RT-PCR sensitivity values in the laboratory confirmed and high suspicion group combined according to specimen type in the first SARS-CoV-2 RT-PCR test.

**eTable 4.** Estimated SARS-CoV-2 RT-PCR sensitivity values in the laboratory confirmed, and in the laboratory confirmed and high suspicion group combined according to delay (days) from symptom onset to first SARS-CoV-2 RT-PCR test.

**eFigure 1.** Number of SARS-CoV-2 RT-PCR tests conducted at the HUSLAB Clinical Microbiology laboratory, and positivity rate over the study period 4 March – 15 April 2020. Median and mean positivity rates were 9.6% and 10%, respectively.

**eFigure 2.** Age distribution of the study population as histograms. A. Inpatients. B. Outpatients.

**eFigure 3** Delay to first SARS-CoV2 RT-PCR test (days) in the laboratory confirmed cases and the high suspicion group. A. Inpatients B. Outpatients.

**eFigure 4** Visualisation of clinical sensitivity estimates for inpatients and outpatients according to specimen type.

**eTable 1.** List of SARS-CoV-2 RT-PCR testing criteria over the study period.

Time period	SARS-CoV-2 testing criteria	Epidemic areas
March 6 <sup>th</sup> - March 9 <sup>th</sup> 2020	1) Clinical picture of an acute respiratory infection: e.g. fever and/or cough and/or breathing difficulty and/or pneumonic imaging finding  AND 2) Possible exposure: travel to epidemic area or contact with laboratory confirmed  OR 3) Admission to ICU for respiratory infection, causative agent unknown	Mainland China, South Korea, Iran, Italy
March 9 <sup>th</sup> - March 15 <sup>th</sup> 2020	Same as 6 March with an expanded epidemic area	Mainland China, South Korea, Iran, Italy, <i>Tyrol, Nordrhein-Westfalen (Germany)*</i>
March 15 <sup>th</sup> - March 22 <sup>nd</sup> 2020	1) Quarantined individual experiencing symptoms of respiratory infection;  2) Admission to hospital for respiratory infection, causative agent unknown;  3) Individual over the age of 70 presenting with symptoms of respiratory infection;  4) Symptoms of respiratory infection AND possible exposure: travel or contact with lab. confirmed;  5) Nursing home resident with symptoms of respiratory infection AND suspicion of a respiratory infection epidemic in the facility	Italy, Tyrol  From 16 March onwards, all non-essential travel to and from Finland is prohibited
March 22 <sup>nd</sup> - April 13 <sup>th</sup> 2020	Same as 15 March and 6) health care personnel with symptoms of respiratory infection	No designated epidemic areas; all travel considered a risk
April 13 <sup>th</sup> 2020 onwards	1) All individuals experiencing either respiratory or gastrointestinal symptoms;  2) Patients belonging to risk groups that are admitted to hospital for any reason	

\*New areas in cursive

**eTable 2.** List of COVID-19 cohort wards. Inpatients were admitted to these COVID-19 cohort wards during the study period. Both laboratory confirmed and suspected COVID-19 patients were admitted to the cohort wards, except for two wards (COV\_KNKINF and COV\_KITEHO) to which only laboratory confirmed cases were admitted.

Name of the ward	City	Hospital	Type of ward	Date when started as a cohort ward
MEKINFOS	Helsinki	Meilahti hospital area	ward	4.3.2020
MEKINFOSK4B	Helsinki	Meilahti hospital area	ward	4.3.2020
MEKKEU6A	Helsinki	Meilahti hospital area	ward	16.3.2020
MEKKEU6B	Helsinki	Meilahti hospital area	ward	23.3.2020
COV_MEKOS5	Helsinki	Meilahti hospital area	ward	1.4.2020
MAOS5	Helsinki	Malmi Hospital	ward	13.3.2020
PES4K	Vantaa	Peijas Hospital	ward	30.3.2020
JOKEU5	Espoo	Jorvi Hospital	ward	15.3.2020
HYINFB-4	Hyvinkää	Hyvinkää Hospital	ward	8.4.2020
RAUPPAVD	Raasepori	Raasepori Hospital	ward	23.3.2020
COV_KNKINF	Helsinki	Surgical Hospital	ward	15.4.2020
COV_KITEHO	Helsinki	Surgical Hospital	ICU	9.4.2020
MEM1	Helsinki	Meilahti hospital area	ICU*	**
PET	Vantaa	Peijas Hospital	ICU*	**
PEPV	Vantaa	Peijas Hospital	ICU*	**
JOU2	Espoo	Jorvi Hospital	ICU*	**
HYTEHVA	Hyvinkää	Hyvinkää Hospital	ICU*	**
POPPKL	Porvoo	Porvoo Hospital	emergency department*	**

\*Due to lack of patient lists of ICUs or one cohort ward at Porvoo Hospital, all inpatients with SARS-CoV-2 RT-PCR taken at ICUs or at the emergency department of Porvoo Hospital were included.

\*\* All tests taken from 4 March to 15 April included.

**eTable 3.** Estimated SARS-CoV-2 RT-PCR sensitivity values in the laboratory confirmed and high suspicion group combined according to specimen type in the first SARS-CoV-2 RT-PCR test.


<b>Specimen type*</b>	<b>Inpatients Sensitivity (95 % CI)</b>	<b>Outpatients Sensitivity (95 % CI)</b>	<b>All Sensitivity (95 % CI)</b>
Nasopharyngeal	195/274	154/458	349/732
	<b>71.2 %</b>	<b>33.6 %</b>	<b>47.7 %</b>
	(65.5 – 76.2 %)	(29.4 – 38.1 %)	(44.1 – 51.3 %)
Oropharyngeal	36/54	39/97	75/151
	<b>66.7 %</b>	<b>40.2 %</b>	<b>49.3 %</b>
	(53.4 – 77.8 %)	(31.0 – 50.2 %)	(41.5 – 57.2 %)
Not known	47/84	41/117	88/201
	<b>56.0 %</b>	<b>35.0 %</b>	<b>43.8 %</b>
	(45.3 – 66.1 %)	(27.0 – 44.0 %)	(37.1 – 50.7 %)

\* Other sample types (Brocho-alveolar lavage, sputum, and tracheal aspirate) were excluded from analysis (n=4 for inpatients, n=2 for outpatients). Specimen type was unknown for 84 inpatients and 117 outpatients.

**eTable 4.** Estimated SARS-CoV-2 RT-PCR sensitivity values in the laboratory confirmed, and in the laboratory confirmed and high suspicion group combined according to delay (days) from symptom onset to first SARS-CoV-2 RT-PCR test.


Delay (days) from symptom onset to sampling	No of patients with first RT-PCR positive	No of COVID-19 Laboratory confirmed patients	No of COVID-19 High suspicion patients	Total no of COVID-19 Laboratory confirmed and high suspicion patients	Sensitivity for COVID-19 Laboratory confirmed patients % (95 % CI)	Sensitivity for COVID-19 Laboratory confirmed + High suspicion patients % (95 % CI)
<1 day	29	37	21	58	78.4 (62.8 - 88.6)	50.0 (37.5 - 62.5)
1-2 days	118	129	132	261	91.5 (85.4 - 95.2)	45.2 (39.3 - 51.3)
3-4 days	96	102	99	201	94.1 (87.8 - 97.3)	47.8 (41.0 - 54.6)
5-6 days	77	88	55	143	87.5 (79.0 - 92.9)	53.8 (45.7 - 61.8)
7-14 days	153	172	136	308	89.0 (83.4 - 92.8)	49.7 (44.1 - 55.2)
>14 days	10	13	26	39	76.9 (49.7 - 91.8)	25.6 (14.6 - 41.1)
No data	33	33	47	80	100 (89.6 - 100)	41.2 (31.1 - 52.2)
Total	516	574	516	1090	89.9 (87.2 - 92.1)	47.3 (44.4 - 50.3)

**eFigure 1.** Number of SARS-CoV-2 RT-PCR tests conducted at the HUSLAB Clinical Microbiology laboratory, and positivity rate over the study period 4 March – 15 April 2020. Median and mean positivity rates were 9.6% and 10%, respectively.




**eFigure 2.** Age distribution of the study population as histograms. A. Inpatients. B. Outpatients.

A




B




**eFigure 3** Delay to first SARS-CoV2 RT-PCR test (days) in the laboratory confirmed cases and the high suspicion group. A. Inpatients B. Outpatients.

A



B





**eFigure 4** Visualisation of clinical sensitivity estimates for inpatients and outpatients according to specimen type.

